Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
63
Language
English
Published on
21/02/24
You may also be interested by these reports :
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...
12/11/26
Ottobock delivered a solid 3Q26, in line on sales and slightly ahead on profitability. Core revenues grew by +9.0% to €433.4m (organic +6.4%). B2B ...
11/11/26
The Q3 sales and profitability met expectations; however, a slight guidance downgrade disappointed investors. Healthy growth in all sub-segments was ...
09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...